국가: 남아프리카
언어: 영어
출처: South African Health Products Regulatory Authority (SAHPRA)
Ranbaxy
REFTAX 500 (Injection) REFTAX 1g (Injection) SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): REFTAX 500 (Injection) REFTAX 1g (Injection) COMPOSITION: Reftax 500 Each vial contains: Cefotaxime sodium (Sterile) equivalent to cefotaxime 500 mg Reftax 1g Each vial contains: Cefotaxime sodium (Sterile) equivalent to cefotaxime 1g PHARMACOLOGICAL CLASSIFICATION: A20.1.1 Broad and medium spectrum antibiotics PHARMACOLOGICAL ACTION Mechanism of action Cefotaxime is a third-generation cephalosporin antibiotic. The bactericidal action of cefotaxime results from inhibition of cell wall synthesis of the bacterial cell wall. Antibacterial spectrum Cefotaxime has in vitro activity against a wide range of gram-positive and gram-negative organisms. Cefotaxime has a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. Cefotaxime is active against the following microorganisms in vitro (In vitro sensitivity does not necessarily imply in vivo efficacy): Gram-positive aerobes: Staphylococcus aureus, including certain penicillinase and non-penicillinase producing strains, Staphylococcus epidermidis, Streptococcus pyogenes (Group A beta-hemolytic streptococci), Streptococcus agalactiae (Group B streptococci) (Note: most strains of enterococci e.g. S. faecalis are resistant), Streptococcus pneumoniae. Gram-negative aerobes: Citrobacter spp., Enterobacter spp., Escherichia coli, Haemophilus influenzae (including ampicillin-resistant H. influenzae),Klebsiella spp. (including K. pneumoniae), Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, Proteus morganella, Proteus rettgeri, Providencia spp., Serratia spp., Salmonella spp.(including S .typhi), Shigella spp. Anaerobes: Bacteroides spp., Clostridiu 전체 문서 읽기